Phase 2 Colorectal Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have given written consent and are willing to follow the study procedures
• People aged 18 or older
• People who have been diagnosed with colorectal adenocarcinoma (a specific type of bowel cancer), confirmed through laboratory testing of tissue
• People whose cancer is locally advanced — meaning it has grown into nearby tissue or nearby lymph nodes — confirmed by CT or MRI scan
• People whose tumour has a specific biological feature called dMMR or MSI-H, identified through laboratory testing (this relates to how the cancer cells repair their DNA)
• People who have not yet received any treatment for their colorectal cancer, including surgery, chemotherapy, targeted therapy, or radiation
• People whose major organs (such as kidneys, liver, and bone marrow) are functioning adequately
• People whose general physical condition is strong enough to carry out light activity and self-care (confirmed through a standard medical assessment scale)
• Women who could become pregnant must have a negative pregnancy test and agree to use contraception during and for 3 months after treatment; men with partners who could become pregnant must also agree to use contraception
• People who are willing and able to follow all study requirements

Who may not be able to join:

• People whose cancer has spread to distant parts of the body, confirmed by CT, MRI, or PET-CT scan
• People with a complete bowel blockage, active bleeding, or a bowel perforation that requires emergency surgery
• People whose primary tumour cannot be fully removed by surgery
• People who currently have, or have a history of, another cancer — unless it was fully treated 5 or more years ago, or was a very early-stage cancer that was adequately treated
• People who have previously received certain immunotherapy drugs that target specific immune system pathways (such as anti-PD-1, anti-PD-L1, or anti-CTLA-4 treatments)
• People who have had major surgery or a serious injury within the 4 weeks before joining the trial, or whose surgical wound has not fully healed
• People who have had a blood clot-related event — such as a stroke, mini-stroke, blood clot in the lungs, or deep vein thrombosis — within the past 12 months
• People who have had a heart attack or newly diagnosed chest pain (angina) within the past 12 months, or who have active coronary artery disease
• People with moderate to severe heart failure (confirm with trial site)
• People with HIV, AIDS, or untreated active hepatitis B or C
• People with active inflammatory bowel disease or another bowel condition that causes ongoing diarrhoea
• People with an active autoimmune disease — though some stable, well-managed conditions such as type 1 diabetes, an underactive thyroid, vitiligo, psoriasis, or hair loss may be exceptions (confirm with trial site)
• People with active lung disease such as interstitial lung disease, non-infectious lung inflammation, pulmonary fibrosis, or acute pneumonia, or other uncontrolled conditions such as uncontrolled diabetes or high blood pressure
• People who still have significant side effects (Grade 2 or higher) from a previous treatment, with the exception of anaemia, hair loss, or skin pigmentation changes
• People with a known or suspected allergy to any of the drugs used in the study
• People who are pregnant or breastfeeding
• Women who could become pregnant, or men with partners who could become pregnant, who are unwilling to use effective non-hormonal contraception
• People with any unstable health condition that could affect their safety or ability to follow the study protocol

Important: Always verify eligibility with the trial site directly before applying.